Literature DB >> 6776913

Methylprednisolone pulse therapy for nonrenal lupus erythematosus.

S Eyanson, M H Passo, M A Aldo-Benson, M D Benson.   

Abstract

High-dose intravenous methylprednisolone therapy has previously been shown to be efficacious in the treatment of renal lupus erythematosus. The present report presents 2 patients with life-threatening, nonrenal lupus erythematosus. One patient had coma and seizures, while the other had sever thrombocytopenia and anaemia. Both had failed to respond to oral corticosteroid therapy in high doses but had dramatic clinical responses with intravenous methylprednisolone given in 'pulses.' Possible mechanisms of clinical improvement are discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776913      PMCID: PMC1000560          DOI: 10.1136/ard.39.4.377

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Human lymphocyte subpopulations. Effect of corticosteroids.

Authors:  D T Yu; P J Clements; H E Paulus; J B Peter; J Levy; E V Barnett
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  "Pulse" methylprednisolone therapy in the treatment of severe glomerulonephritis.

Authors:  B R Cole; J T Brocklebank; R A Kienstra; J M Kissane; A M Robson
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

3.  Reversal of renal allograft rejection with intravenous methylprednisolone "pulse" therapy.

Authors:  N J Feduska; J G Turcotte; P W Gikas; G E Bacon; J A Penner
Journal:  J Surg Res       Date:  1972-03       Impact factor: 2.192

4.  Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone.

Authors:  P R Bell; J D Briggs; K C Calman; A M Paton; R F Wood; S G Macpherson; K Kyle
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

5.  Corticosteroids and lymphoid cells.

Authors:  H N Claman
Journal:  N Engl J Med       Date:  1972-08-24       Impact factor: 91.245

6.  Intravenous methylprednisolone pulses in diffuse proliferative lupus nephritis.

Authors:  T Nebout; A Sobel; G Lagrue
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321

7.  Serum immune complexes and disease activity in lupus nephritis.

Authors:  R J Levinsky; J S Cameron; J F Soothill
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

8.  Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis.

Authors:  E S Cathcart; B A Idelson; M A Scheinberg; W G Couser
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321

9.  Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone.

Authors:  W T Butler; R D Rossen
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

Review 10.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations.

Authors:  A S Fauci; D C Dale; J E Balow
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

View more
  14 in total

1.  Pulsed methylprednisolone.

Authors:  A Oto; T Sozen; S Boyacioglu
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

2.  A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.

Authors:  J C Edwards; M L Snaith; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

Review 3.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  A case of diffuse lupus encephalopathy successfully treated with high-dose intravenous methylprednisolone.

Authors:  G Di Iorio; U Picillo; P Santanelli; S Migliaresi; V Bonavita
Journal:  Ital J Neurol Sci       Date:  1992-04

Review 5.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT.

Authors:  S S Sun; W S Huang; J J H Chen; C P Chang; C H Kao; J J Wang
Journal:  Eur Radiol       Date:  2003-12-09       Impact factor: 5.315

7.  Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus.

Authors:  D A Isenberg; W J Morrow; M L Snaith
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

8.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

9.  Response of acute cerebral lupus in childhood to pulse methylprednisolone in reduced dosage.

Authors:  O Hanmer; D Saltissi
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

10.  Transient life-threatening cerebral edema in a patient with systemic lupus erythematosus.

Authors:  Matt T Bianchi; Catherine Lavigne; Farzaneh Sorond; Bonnie Bermas
Journal:  J Clin Rheumatol       Date:  2009-06       Impact factor: 3.517

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.